Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 12
Healthy volunteers: yes

Brief summary:
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

Detailed description:

Arms:
arm 1: Sitagliptin anhydrous formulation arm 2: Sitagliptin monohydrate FMI formulation

Interventions: intervention 1: Sitagliptin phosphate anhydrous formulation intervention 2: Comparator: sitagliptin phosphate monohydrate form
Intervention descriptions: intervention 1: Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods. intervention 2: Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.

Protocol document: